Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) was the recipient of a significant increase in short interest in the month of July. As of July 31st, there was short interest totalling 39,500 shares, an increase of 9.7% from the June 30th total of 36,000 shares. Based on an average daily trading volume, of 9,100 shares, the days-to-cover ratio is currently 4.3 days. Currently, 1.7% of the company’s shares are sold short.
Several brokerages have recently weighed in on ETTX. Zacks Investment Research downgraded Entasis Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, May 20th. ValuEngine upgraded Entasis Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $16.50.
A hedge fund recently bought a new stake in Entasis Therapeutics stock. BlackRock Inc. acquired a new position in Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 13,755 shares of the company’s stock, valued at approximately $56,000. BlackRock Inc. owned approximately 0.11% of Entasis Therapeutics as of its most recent SEC filing. 65.04% of the stock is currently owned by institutional investors and hedge funds.
Entasis Therapeutics (NASDAQ:ETTX) last announced its quarterly earnings data on Monday, August 12th. The company reported ($1.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.44). On average, sell-side analysts anticipate that Entasis Therapeutics will post -3.39 earnings per share for the current fiscal year.
About Entasis Therapeutics
Entasis Therapeutics Holdings, Inc operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin.
Read More: Systematic Risk and Investors
Receive News & Ratings for Entasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.